VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

VEGF-B helps nerve cells cheat death without unwanted side effects

The prototypical member of the VEGF family of proteins, VEGF, has recently been shown to protect cells in the nervous system from death and degeneration.

8 Feb 2008

Lymphangioleiomyomatosis - potential clues into the treatment and diagnosis

Studies published in the Jan. 10 edition of the New England Journal of Medicine (NEJM) are providing clues into the treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive and deadly lung disease that affects women in their childbearing years.

11 Jan 2008

Bevacizumab found to improve survival for patients with advanced breast cancer

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy.

28 Dec 2007

Avastin shows promise for brain cancer

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

17 Dec 2007

Drug study for brain cancer shows promising results

14 Dec 2007

Depression nearly triples the risk of death following a heart attack

...even when accounting for other heart attack risk factors, according to research presented at the American College of Neuropsychopharmacology (ACNP) annual meeting, which showed that among 360 depressed, post myocardial infarction patients followed for more than six years, those who did not recover from their depression in the first six months were more than twice as likely to die.

10 Dec 2007

Lymphatic vessel and lymph node function are restored with growth factor treatment

The frequent spread of certain cancers to lymph nodes often necessitates surgery or radiation therapy that damages the lymphatic system and can cause lymphedema, a condition of localized fluid retention that often increases susceptibility to infections.

4 Dec 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

How can we know early who will benefit from tumor target therapy?

The precise tailoring of tumor target treatment for patients with cancer is an unmet challenge.

21 Nov 2007

Hormone norepinephrine may hasten the progression of certain blood cancers

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

20 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

New approaches to wet age-related macular degeneration treatment

Two particularly notable research presentations at the American Academy of Ophthalmology's Annual Meeting described new approaches to the treatment of "wet" Age-Related Macular Degeneration (AMD), the most common cause of severe vision loss in the western world in people over age 50.

13 Nov 2007

Antibody might help starve cancerous tumors

An antibody might offer a safe and effective complement to anti-cancer therapies designed to starve malignant tumors by pruning the blood vessels that feed them, researchers report in the November 2 issue of the journal Cell, a publication of Cell Press.

2 Nov 2007

SENP1 protein may provide a basis for future targeted cancer therapies

Researchers at the University of Texas M. D. Anderson Cancer Center have found a protein that enables cellular survival during periods of low oxygen, or hypoxia, which also is key for development of many kinds of cancer.

2 Nov 2007

Blood markers can help choose best dose for antiangiogenic drugs

Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth.

25 Oct 2007

Low-density lipoprotein may contribute to vascular diseases

Low-density lipoprotein (LDL), a transporter of cholesterol, may also contribute to vascular diseases by a previously unidentified mechanism, according to a report published online this week in EMBO reports.

25 Oct 2007

Transparent zebrafish help the study inflammatory breast cancer

What if doctors could peer through a patient's skin and see a cancer tumor growing? They'd be able to study how tumor cells migrate: how they look, how they interact with the blood system to find nourishment to grow and spread through the body.

22 Oct 2007

Researchers specifically manipulate tumor angiogenesis gene

Angiogenesis is a common process that is essential for tumor growth beyond 2 mm. Although numerous growth factors are involved, vascular endothelial growth factor (VEGF), particularly VEGF-A, has been shown to play an important role in tumor angiogenesis.

16 Oct 2007

Research shows how stem cells decide to become either skeletal or smooth muscle

Researchers have discovered a key protein that controls how stem cells "choose" to become either skeletal muscle cells that move limbs, or smooth muscle cells that support blood vessels, according to a study published in the Proceedings of the National Academy of Sciences (PNAS).

11 Oct 2007

Rapamycin and Gleevec reverses effects of portal hypertension in rats

A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats.

2 Oct 2007